Chimeric Antigen Receptor T-Cell Therapy for Diffuse Large B-Cell Lymphoma / 대한내과학회지
Korean Journal of Medicine
;
: 152-158, 2019.
Artigo
em Coreano
| WPRIM
| ID: wpr-759927
ABSTRACT
CD19 chimeric antigen receptor T-cell (CAR-T) therapy, a genetically engineered cell therapy, showed unprecedented efficacy in the treatment of relapsed or refractory diffuse large B-cell lymphoma. Two agents, axicabtagene ciloleucel and tisagenlecleucel, were approved by the Food and Drug Administration in 2017. However, CAR-T therapy is a treatment with complex logistics and high costs, as well as inherent adverse events, including cytokine-release syndrome and neurotoxicity. In addition, predictive biomarkers for efficacy and toxicity are lacking. Industry-academy cooperation is urgently required to develop CAR-T therapy that is effective, safe, and affordable for patients in Korea.
Texto completo:
DisponíveL
Índice:
WPRIM (Pacífico Ocidental)
Assunto principal:
Organização e Administração
/
United States Food and Drug Administration
/
Linfócitos B
/
Receptores de Antígenos
/
Linfócitos T
/
Biomarcadores
/
Linfoma de Células B
/
Linfoma Difuso de Grandes Células B
/
Terapia Baseada em Transplante de Células e Tecidos
/
Coreia (Geográfico)
Tipo de estudo:
Estudo prognóstico
Limite:
Humanos
País/Região como assunto:
Ásia
Idioma:
Coreano
Revista:
Korean Journal of Medicine
Ano de publicação:
2019
Tipo de documento:
Artigo
Similares
MEDLINE
...
LILACS
LIS